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Abstract
Biosensing technology is an advancing field that benefits from the properties of biological
processes  combined to  functional  materials.  Recently,  biosensors  have emerged as
essential tools in biomedical applications, offering advantages over conventional clinical
techniques for diagnosis and therapy. Optical biosensors provide fast, selective, direct,
and cost-effective analyses allowing label-free and real-time tests. They have also shown
exceptional potential for integration in lab-on-a-chip (LOC) devices. The major chal‐
lenge in the biosensor field is to achieve a fully operative LOC platform that can be used
in any place at any time. The choice of an appropriate strategy to immobilize the biological
element on the sensor surface becomes the key factor to obtain an applicable analytical
tool. In this chapter, after a brief description of the main biofunctionalization proce‐
dures on silicon devices, two silicon-based chips that present an (i) IgG antibody or (ii)
an Id-peptide as molecular probe, directed against the B-cell receptor of lymphoma cancer
cells, will be presented. From a comparison in detecting cells, the Id-peptide device was
able to detect lymphoma cells also at low cell concentrations (8.5 × 10−3 cells/μm2) and in
the presence of a large amount of non-specific cells. This recognition strategy could
represent a proof-of-concept for an innovative tool for the targeting of patient-specific
neoplastic B cells during the minimal residual disease; in addition, it represents an
encouraging starting point for the construction of a lab-on-a-chip system for the specific
recognition of neoplastic cells in biological fluids enabling the follow-up of the changes
of cancer cells number in patients, highly demanded for therapy monitoring applications.
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1. Introduction
Biosensing is a scientific and technological hot topic, given its potential in the field of medical
diagnosis [1], healthcare [2], environment [3], defense [4], and food security [5].
Nowadays, the healthcare and pharmaceutical sectors continuously demand more powerful
analytical and diagnostic tools for the identification of disease, the development of new
medicines, and better diagnostic tests. In these fields, the specific and sensitive detection of
targets in short-time analyses plays a key role. While a number of commercial bioassay kits
are already on the market, there still remains a major challenge to develop novel biodetec‐
tion methods to meet the ever-increasing request. High-capability optical biosensing sys‐
tems are actually emerging as a way to reach this aim [6].
Optical biosensing is a powerful analytical tool used to detect optical changes upon the
interaction between an analyte of interest and its ligand, previously immobilized on the
sensing device as biological probe; the intensity of obtained signal can be measured, and its
value is a function of the analyte concentration in the sample [7, 8]. Generally, optical
biosensors use two different detection protocols: direct detection of the analyte (label-free
detection) or indirect detection through optically labeled probes (label-based detection). In
label-based detection, fluorescent, enzymatic, or radioactive tags, linked on target or on probe
molecules, are used; the intensity of the signal indicates the presence of analyte and the
interaction with the recognition molecule. This type of detection is extremely sensitive, since
it is possible to detect up a single molecule [9, 10]; nevertheless, complex procedures are needed
for labeling, and they may interfere with the functionality of the target molecule. In contrast,
in label-free detection, target molecules are not labeled or altered and are free to interact in
their natural forms: Recent progresses in this field are showing promising results [10]. This
strategy is relatively easy and cheap to perform and allows for quantitative and kinetic
measurement of molecular interactions. These advantages, with low detection limit, non-
destructive approach, and with the ability to recognize a wide variety of analytes or multi‐
ple analytes at the same time with fast signal monitoring and analysis [11], make label-free
optical detection one of the leading recognition methods in the biosensor field.
Label-free biosensors are very versatile platforms, since they can be developed in different
materials, such as silicon or its compounds, glasses, metals, or polymers, and they offer
different detection modes and configurations that can be combined [12]. In perspective, optical
label-free biosensors are expected to replace fluorescent biosensors in DNA micro-arrays and
lab-on-a-chip (LOC) applications [13–15].
The use of silicon-based technology—the same developed for microelectronics—could allow
the integration of microfluidic circuits for analyte handling, sensing elements, and control/
reading electronics into a single chip. This could pave the way to the mass production of micro
total analysis systems and LOCs capable to provide rapid, sensitive, and multiplexed
measurements in any place at any time.
The selection of the biological element to immobilize on the sensor surface is dictated by the
application and must be chosen to be highly specific for the target molecule and stable enough
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to be immobilized without losing functionality. Several types of routes can be used to
biofunctionalize the sensor surface [16], and the choice of an appropriate immobilization
procedure has become a key factor in the biosensor area. An ideal immobilization procedure
should guarantee an efficient coverage by the molecular probes of the sensing layer without
interfering with their properties (structure, biological activity, affinity, specificity). In addi‐
tion, the possibility to preserve their stability in normal storage conditions and also for
regeneration could be useful in the case of integration in portable LOC. Despite enormous
research efforts have been made to find novel strategies according to the application, a
universally valid procedure has not yet been developed and the realization of cheap hand‐
held platforms is almost limited. For this reason, the choice of the most effective strategy of
immobilization represents the critical step that turns a sensing device into an applicable
analytical tool with the required quality standards. Currently, a lot of biomolecules can be used
as bioreceptors (antibodies, nucleic acid, peptides, enzymes, cell receptors, and many others).
Among these, artificial peptides provide an opportunity to develop the desired molecular
biosensor due to their desirable properties such as diversified structure, high affinity to
ligands, matured synthesis protocol, and modified approach [17].
2. Biosensing application in cancer
Cancer is one of the main causes of death worldwide. Early diagnosis is the key to enhance
the success of medical treatment. In the last few years, in parallel with a growing interest in
detecting cancer cells, a wide variety of techniques were developed for detection at the cellular
level [18–21]; nevertheless, most of these modalities are expensive and time-consuming, and
they are often associated to risks deriving from radioactive tracers.
At this point, despite some considerable achievements, the realization of simple, rapid, non-
destructive, and low cost methods for early detection of cancer and minimal residual disease,
important for diagnosis and reduction in mortality for certain cancers, still remains an
unfulfilled goal [22, 23]. To meet these specific requirements, biosensors have attracted
increasing attention since biosensing technology, taking advantage of the properties of
biological systems combined to functional advanced materials, is providing rapid, reprodu‐
cible, and highly sensitive cell detection.
Among the various types of cancer, lymphoma is the most common blood cancer, which
incidence is recently increasing. This malignancy is a clonal expansion of neoplastic cells that
may result in fatal outcomes [24]. Despite the great progress that has been made over the last
several decades in the treatment of lymphoma, the prognosis for patients with particular sub-
types of disease remains quite poor. Lymphomas are a heterogeneous group of tumors arising
in the reticuloendothelial and lymphatic systems. The major types are Hodgkin lymphoma
and non-Hodgkin lymphoma. Great progresses in the use of monoclonal antibodies, chemo‐
therapy, radioimmunotherapy, and peripheral blood stem cell transplants have achieved
significant responses in the treatment of these diseases and also markedly improved the
outcome of the cure among elected sub-populations of patients, since not all the patients or
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subtypes of lymphoma are responsive to these “conventional” approaches. For example,
tumorigenic B-cell lymphomas are sensitive to anticancer treatments, including convention‐
al chemotherapy, radiation therapy, and corticosteroids [25]. Nevertheless, the disease is
associated with incomplete response to clinical treatments that result in a minimal residual
disease in which a few neoplastic cells undetected in vivo replenish the cancer cell reservoir.
This grim scenario calls for novel strategies to detect tumorigenic B cells. Random peptide
libraries (RPLs) allow the selection of therapeutic peptides for tumor cell-surface receptors.
Idiotypic determinants of the Ig-BCR, expressed by lymphoma cells, function as a specific
tumor antigen that may be exploited for cell-specific detection or targeted therapy. Here, we
present the complex different strategies that we adopted in order to construct a biosensor for
the detection of tumorigenic lymphoma B cells and discuss all the difficulties that we encoun‐
tered and the approaches we adopted for their overcoming.
3. The choice of appropriate support for biosensing
Our vision was to create a highly sensitive, label-free optical biosensing system for the targeting
of patient-specific neoplastic B cells during the minimal residual disease. The material used to
develop this unique tool for biosensing include mainly silicon, since it possesses great potential
because of its many unique properties, including biocompatibility, which is an important
precondition for biological and biomedical applications, abundance, tailorable surface
chemistry, and unique electronic, optical, photonic, and mechanical properties, among others.
In addition, high surface-to-volume ratio of silicon derivatives offers exciting opportunities to
design high-performance silicon-based functional devices for biomedical applications.
Moreover, silicon is very abundant on earth allowing inexpensive resources for large-scale and
low-cost preparation for practical applications. Taking advantage of these attractive features,
the interest in the use of silicon is widely grown leading to its applications not only in biology
but also in a lot of other fields [26].
In our research activity, flat silicon devices of fixed thickness (400 μm) were obtained from
highly doped p+ type, 0.003 Ω cm resistivity, (100)-oriented silicon wafers, cut into 10 × 10 mm
square pieces. The wafers were cleaned by a standard RCA process [27] and thermally oxidized
at 1050°C for 5 h. An electrochemical etching process of planar silicon was used to pattern
porous silicon with a high specific surface (up to 500 m2/cm3). An advantage in the use of porous
silicon is that its morphology can be tuned by modification of process parameters [28] so that
the resulting structures can be adapted to obtain the best performance for chemical and
biological processes that happen on their surface. Moreover, the porosity of the material
coupled to the low-cost production makes porous silicon an ideal bulky model system to follow
each functionalization step: The concentration of reagents and molecules in the pores allow to
quantify few nanometers thick films of passivating agents, exploiting signal enhancements,
that cannot easily measured on flat supports.
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4. Chemical functionalization procedures
The selection of an appropriate procedure for the immobilization of a biological element on
the sensor surface that interacts with the desired target for the specific recognition of an analyte
has become a critical step in the biosensor area, and enormous efforts are continuously invested
in order to optimize novel strategies according to the application. The biofunctionalization of
chemical modified surfaces can be achieved in several manners that can be grouped in just two
approaches: (i) direct adsorption and (ii) physical adsorption [29–33]: in both cases, each
immobilization route presents advantages and drawbacks.
In the direct adsorption method, there is no bond formation between probe and device,
reagents are not required so either structure or functionality of biomolecules is not affected.
Nevertheless, the efficiency of this strategy is very low.
The bioreceptor physisorption is a quick and widely used approach to immobilize biomole‐
cules on chip surfaces based on electrostatic, hydrophobic, and covalent interactions. Despite
the efficiency and the simplicity, electrostatic, and hydrophobic approaches are direct fast
methods, since no linker molecules are needed, but are limited to situations that require no
directional orientation of the bioprobes. Moreover, both techniques request long incubation
times and the risk of folding and desorption due to changes of parameters, such as pH, ionic
strength, or temperature, cannot be excluded. The covalent attachment of probe is more
efficient in terms of stability and binding strength. Generally, the binding occurs between a
functional chemical group of the biomolecules, whose blocking does not affect the function‐
ality, and one on the modified surface. For proteins covalent coupling, amino, carboxylic, or
thiol groups are preferred, whereas in the case of nucleic acids, it is possible to take advant‐
age of the versatility of their synthesis to insert reactive groups at the end of the sequence.
More difficult is the immobilization of immunoglobulins in a correct orientation, which can
be achieved by controlled linkage of carbohydrates groups in the constant region or using
affinity proteins (such as A or G Protein) [31]. In all physical adsorption types, a chemical
modification of the platform surface is required to the extent that the material properties are
tuned to accomplish the best analytical characteristics.
The drawing up of an efficient and correct immobilization procedure is a crucial point to avoid
a wide variety of factors that may negatively affect the biosensor functionality. The orienta‐
tion of probe, the density of coating on the detection surface, pH, target concentration,
operating conditions, and chemical environment provided by transducer must be closely
explored. An efficient biofunctionalization process should take in account few important
observances: The preservation of the molecular probe structure to guarantee subsequent
binding of analyte; limited chemical steps and minimal consumption of reagents and sam‐
ples to make the whole procedure lean and easily reproducible; low optical adsorption at the
working wavelengths; homogeneously thin layer formation compatible with evanescent field
sensing; uniform surface coating; saturation of eventually free binding sites to reduce the
possibility of false-positive signals; biocompatible conditions; integrability with large-scale
fabrication. The exploration of these traits offers the possibility to improve biosensors features
increasing the power of detection.
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Figure 1. Types of silicon surface chemical modifications for biosensors: (a) organosilane-based, (b) phosphonate-
based, and (c) glutaraldehyde-based strategies.
Figure 1 represents the main functionalization approaches employed to construct integrated
optics (IO) biosensors. Before the biofunctionalization step, a previous chemical activation of
the sensor surface is always needed. To this aim, our group employed the self-assembly of
organofunctional alkoxysilanes (Figure 1a), an easy and versatile system for organic conju‐
gating [34]. However, silicon-based surfaces require a prior activation step to oxidize the
surface and to expose the silanol groups for cross-linking with the silane. The formation of a
thin silane self-assembled film allows applying a great number of chemical reactions.
Immediately before silanization, surfaces are cleaned with oxidant media to remove organic
pollutants and to increase the hydroxyl moieties on the surface [35]. The used oxidant is
piranha solution [36–39], consisting of a concentrated sulfuric acid mixed with hydrogen
peroxide at 3:1 ratio. This treatment is performed by heating for 30 min only. Hundreds of
different organosilanes with different structures and functionalities are nowadays commer‐
cially available, although the most commonly employed are those with short alkyl chain that
present an amino, thiol, epoxy, or carboxylic group at the terminus. Among this vast variety
of compounds, 3-aminopropyltriethoxysilane (APTES) was chosen for its reactivity to
aldehyde, carboxylic acid, and epoxy functionalities.
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The reaction between the oxidized surface and the organosilane is based on the condensa‐
tion between the Si–O–Si of the silane and the OH present on the device; generally, besides the
hydroxyl groups already present on the native silicon oxide layer, a thermal oxidation is a
common procedure to form a new efficient oxide film [40–42] in order to assure a plenty of
silanol groups for an efficient coverage of the organic layer.
Furthermore, after silanization, APTES layer was cured at high temperature [43]. The
aminosilane is more reactive, and it can be applied on a surface using pure organic solvent.
The advantage of the curing is that a more controlled deposition of the compound can be
obtained to create a thinner film of the aminopropyl groups on the chip. The self-assembled
monolayers generally present a thickness in the range of 1–3 nm and create a nanometer-scale
organic thin coat [44, 45].
5. Choice of biomolecular probe
At this point, a wide variety of biomolecules (antibodies, nucleic acid sequences, peptides,
enzymes, cell receptors) can be used as bioreceptors (Figure 2).
Figure 2. Types of bioconjugation methods on aminated surfaces: (a) N-hydroxysuccinimide–based, (b) succinic anhy‐
dride–based, (c) p-phenylenediisocyanate–based, and (d) glutaraldehyde-based strategies.
The choice of bioreceptor depends on the intended application of biosensor and it must meet
two important requirements: high specificity for the target molecule and high stability to retain
its biological activity when immobilized on the support.
A first biofunctionalization approach, based on the covalent bind of a biomolecule on the
activated silicon sensor surface, included the use of an IgG antibody as molecular probe
directed against B-cell receptor. The chip was treated with the homobifunctional cross-linker
glutaraldehyde (GA): This molecule, besides to be employed to form an aldehyde-terminat‐
ed surface, which allows the reaction of amine groups, by the formation of imines (Schiff bases),
acts as spacer in order to keep away from the surface the immobilized bioprobe that can react
freely with target molecules [46, 47]. By this strategy, the antibody has been immobilized on
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the surface via protein A in an oriented fashion [48]. The whole process is checked monitor‐
ing surface changes by ellipsometric measurements and FTIR spectromicroscopy. As report‐
ed in Table 1, using a random sampling of four different wells, it was observed for all of them
after each functionalization step the surface layer thickness.
Thickness (nm)
Film Sample 1 Sample 2 Sample 3 Sample 4
Oxide 75.8 ± 0.4 72.4 ± 0.2 75.0 ± 0.3 73.4 ± 0.2
Aptes + GA 3.0 ± 0.4 3.1 ± 0.3 3.1 ± 0.3 2.1 ± 0.2
Protein A 0.68 ± 0.09 0.67 ± 0.08 0.75 ± 0.1 0.85 ± 0.1
χ2 0.54 0.43 0.47 0.45
Table 1. Surface layer thickness on four random samples after each step of functionalization measured by ellipsometry
technique.
The analyses of the FT-IR spectra led to the identification of several characteristic vibration
bands that were coherent with the various functionalization steps. Table 2 reports a list of the
major bands identified together to peak assignment.
Predicted peak Frequency cm−1
Sample 1 Sample 2 Sample 3 Sample 4 Sample 5 Sample 6
Si–O str – 1127 – – – –
Si–O–C as str – – 1250 1250 1258 1258
–(CH2)–str – – 1295–1305 – – –
–O–CH2–str – – 1445–1475 – – –
Amide II – – – – – 1531
C=O str – – – – 1635 1642
Saturated primary ammine (–NH2 def) – – 1650 – – –
Amide I C=O str – – – – 1650–1680 1638–1687
C=O str – – – – 1685–1705 1774
N–H str – – – – – 3121
Primary ammine –NH2 str – – 3250–3677 – – –
Table 2. Major bands identified by FTIR spectromicroscopy and corresponding assigned peaks.
As experimental model, it was chosen a murine lymphoma cell line (A20) [49] that expresses
high levels of membrane IgG. The most interesting point of this first approach is that the
microfabricated biochip appears to be suitable to reveal specific bindings such as that between
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cell-surface proteins (receptor) and corresponding specific antibody. In addition, the num‐
ber of cells detected by the devices was 2.0 × 10−3 cells/μm2.
Anyway, since this detection limit does not seem satisfactory and the idea that the contact
probability between cells and antibodies on capture specific surface could be improved, we
took advantage of a new functionalization strategy exploiting an Id-peptide as biomolecular
probe. The choice of an Id-peptide was dictated by two main reasons: (i) Artificial peptides
provide an opportunity to develop the desired molecular biosensor due to their desirable
properties such as diversified structure and high affinity [50]. In addition, peptides with
specific sequences can provide high affinity to particular ligands and be obtained by screen‐
ing and optimization of artificial peptide libraries; (ii) the used idiotype peptide is a small
peptide ligand able to be recognized with high affinity and specificity from the B-cell recep‐
tors present on the lymphoma B cells [51–53]. The use of a small ligand as biorecognition
element endowed with great specificity could highly enhance affinity and selectivity of the
detection layer. In addition, it simplifies the functionalization procedure with respect to that
employed for antibodies in which controlling protein orientation is still very challenging [54].
The peptide was immobilized on the silicon surface following the functionalization strategy
schematized in Figure 3.
Figure 3. Functionalization approach utilized on silicon surface to conjugate an Id-peptide to detect lymphoma cells.
After each passivation step, the new synthesized layer is reported in the figure with the same color of the molecule
used in the chemical reaction (APTES is blue, BS3 is red, Id-peptide is green).
This chemical procedure was developed on both crystalline flat and porous silicon samples;
the nanostructured porous was chosen because its peculiar morphology allows the immobi‐
lization of a greater number of molecules with respect to a planar substrate and a number of
functionalization investigation methods could be more easily exploited [55]. The aminosilan‐
ized surface has been activated by the homobifunctional cross-linkers bis[sulfosuccinimidyl]
suberate (BS3), which, acting as spacer, provide succinimidyl-activated carboxyl group that
could react with amine-ended peptide to form an amide bond. Changes in chemical compo‐
sition of PSi surface were monitored by FTIR spectroscopy after each functionalization step
until BS3 (Figure 4).
Bioengineered Surfaces for Real-Time Label-Free Detection of Cancer Cells
http://dx.doi.org/10.5772/62845
187
Figure 4. FTIR spectra of silicon surface after each chemical modification step.
The analysis of the FTIR spectra in the range from 2500 to 500 cm−1 highlighted characteristic
peaks of each molecule used in the different passivation steps, demonstrating the effective‐
ness of the functionalization procedure. Indeed, the characteristic peaks of Si–Hx bonds
corresponding to the PSi after electrochemical etching (2100 and 680–630 cm−1) are no longer
visible when the devices were thermally oxidized, whereas the appearance of the Si–O–Si
characteristic band at 1100 cm−1 was detected.
The formation of the silane film was confirmed by the presence of peaks in the span 1440–1390
cm−1, relative to CH3 from APTES ethoxy moieties, and at 1655 cm−1 relative to an imine group
from oxidation of an amine bicarbonate salt [56]. Moreover, the appearance of the peaks at
1640 and 1550 cm−1 that correspond to CO– and NH– groups of an amide bond, confirms the
deposition of the BS3.
The functionalization of porous silicon surface was also confirmed by spectroscopic reflec‐
tometry.
Figure 5. Reflectivity spectra on porous silicon surface before (solid line) and after APTES silanization (dashed line),
and after BS3 functionalization (short dashed line).
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Reflectivity spectra of porous silicon devices during functionalization steps are reported in
Figure 5. The deposition on pores walls of a thin layer, constituted by the different organic
chemical compounds, produces red shifts of spectra due to the increase of the average
refractive index of porous silicon surfaces [57]. After silanization and cross-linker modifica‐
tion, a red shift of 21 and 15 nm was recorded, respectively. The same chemical modifica‐
tions were performed also on flat silicon devices; in the latter, the whole functionalization
procedure was followed by spectroscopy ellipsometry, in order to quantify layer thickness
variations after thermal oxidation (SiO2), silanization (APTES), and cross-linker functionali‐
zation (BS3). As showed in Table 3, the thickness of oxidized silicon devices was 74 ± 1 nm; this
value increased of 3 and about 2 nm after treatment with aminosilane and BS3, respectively.
Thickness (nm)
Film Sample 1 Sample 2 Sample 3 Sample 4
Oxide 74.9 ± 0.3 74.9 ± 0.2 73.5 ± 0.2 74.7 ± 0.3
Aptes 3.5 ± 0.2 2.9 ± 0.3 3.1 ± 0.2 2.7 ± 0.4
BS3 1.72 ± 0.08 1.84 ± 0.03 1.82 ± 0.03 1.78 ± 0.02
The values reported are the average of five determinations on each sample.
Table 3. Surface layer thickness on four random samples after each step of functionalization measured by ellipsometry
technique.
6. Biosensing
Once the chemical modified silicon chips have been obtained, a procedure to immobilize a
small peptide for label-free detection of cancer cells was settled. The used experimental system
takes advantage of the properties of an idiotype peptide isolated from peptide libraries able
to bind the variable region of the B-cell receptor on A20 lymphoma cells [51]. The selected
peptide, named A20-36 (pA20-36), whose sequence is EYVNCDNLVGNCVI, was linked on
silicon-modified surfaces and used as molecular probe. A random peptide (RND),
SSAYGSCKGPCSSGVHSI, was used as negative control. To determine the optimal peptide
concentration to obtain a uniform coverage of planar and porous surfaces, a titration was
carried out. Based on the obtained results [58], 150 μM concentration was used for both
peptides.
The detection of lymphoma cancer cells fulfilled on both planar and porous peptide-modi‐
fied silicon surfaces is showed in Figure 6. The panels a and b report microscope light images
of the planar device surfaces after incubation with a low (100 cells) or high number (50,000
cells) of A20 cells. The choice of the high number of cells was made in order to have satura‐
tion binding conditions. The same number of cells (50,000) was incubated on A20-36-peptide-
modified porous silicon surface, but a lower number of detected cells were observed on light
microscope (Figure 6, panel c). The chip was not able to bind lymphoma cells when function‐
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alized with RND peptide (Figure 6, panel d), whereas no myeloma cells (5T33MM), a surface
IgG-positive B-cell line unable to bind to pA20-36 peptide [51], were detected when incubat‐
ed on the device functionalized with pA20-36 (Figure 6, panel e).
The number of A20 cells detected on functionalized planar surface device was about 8500 and,
taking in account an average area of 80 μm2 for a single cell, filled ~680,000 μm2, a value
concordant with the available functionalized area (~1.0 × 106 μm2); when the detection was
performed on porous silicon device, the number of cells that effectively bind the chip was
lower (400), filling an area of about 32,000 μm2. The exiguous number of A20 cells on the porous
silicon surface was probably caused by the peculiar morphology of the support; being highly
porous, with pore diameter of about 50 nm, and pore upper edges lower than 1 nm in thickness,
its inner surface is many order of magnitude greater than the top active one. Hence, just a very
low number of peptides are really available on the pore upper edges to bind the cells (that
cannot enter into the pores). Therefore, the consequence of this condition is the decrease in the
number of cells detected on porous silicon biochip resulting lower respect to that on the planar
surface.
Figure 6. Optical images of A20 cell detection on both planar and porous silicon devices. Planar silicon pA20-36 modi‐
fied sensor after incubation with 1 × 104 A20 cells/mL (a) and 5 × 106 A20 cells/mL (b). Porous silicon pA20-36 modified
surface after incubation with 5 × 106 A20 cells/mL (c). Planar silicon RND-modified-sensor after incubation with 5 × 106
A20 cells/mL (d). Planar silicon pA20-36 modified sensor after incubation with 5 × 106 5T33MM cells/mL (e).
The surface of each silicon chip presents a functionalized available area of about 1.0 × 106 μm2
so the maximum number of cells that can be bound on the device was 10,000 (covering an area
of about 800,000 μm2). Since the number of cells detected on planar and porous silicon surfaces
was by count 8500 and 400 (evaluated by optical microscopy), the efficiency of detection is 85
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and 4%, respectively. Moreover, comparing the efficiency of detection of the flat silicon device
based on Id-peptide-BCR recognition with an analogous silicon-based bioanalytical system in
which an anti-IgG-BCR was used as molecular probe [48], it is clear that the first biochip
resulted more efficient in detecting A20 cells (8.5 × 10−3 vs. 2.0 × 10−3 cells/μm2, respectively).
This difference is likely due to the better accessibility of the A20-36 Id-peptide on the BCR with
respect to the anti-IgG. In fact, the binding of the idiotype peptide should occur with the more
exposed variable region of the receptor in contrast with the interaction between IgG and BCR
in which the variable regions of the immunoglobulin bind the less exposed constant region of
the receptor. Furthermore, also the difference in affinity constants between the two ligand-
receptor systems coupled to diverse functionalization approaches might have had a decisive
role in the detection efficiency.
Cell detection was also investigated by atomic force microscopy analysis (AFM) (Figure 7).
Figure 7. Representative AFM image in the trace direction of live A20 cells detected on silicon surface.
Both light microscopy and AFM analysis showed a good biocompatibility of substrate since
viability and cell morphology were not affected.
At this point, since cancerous cells are coexisted with other cell types in the body and it is very
important to selectively differentiate cancer cells from other ones, in order to assess the real
performance of the biochip, lymphoma cells detection was carried out on devices incubated
with mixed samples of A20 and 5T33MM cells (3.5 × 105/mL). The detection of lymphoma cells
in system mixed is reported in Figure 8.
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Figure 8. Detection of A20 cells (green) in system mixed with 5T33MM cells (red) by fluorescence macroscopy after
incubation on planar silicon pA20-36 modified sensor.
The mixed system has been prepared in three different ratios (A20:5T33MM = 1:1, 1:10, 1:100)
of the two labeled live cell lines [59]. The efficiency of detection also in a complex system
demonstrated the high selectivity of the device, confirming that the use of an Id-peptide
immobilized on a silicon-based chip could be a good proof-of-concept for future researches.
7. Conclusions
In this chapter, we focused on the functionalization and activation of crystalline and porous
silicon surfaces to develop devices allowing the identification of specific ligand-receptor
interactions.
As an example, we report new results about the realization of devices suitable to highlight the
specific interaction between cell surface receptors and corresponding specific ligands. One of
these devices was applied to detect the binding of extremely aggressive murine A20 lympho‐
ma cells to a specific IgG antibody as molecular probe directed against B-cell receptor. The
result was encouraging and prompted us to develop an improved device, more sensitive, for
the specific recognition of different types of tumor cells. Another approach was based on the
specificity of an idiotype peptide endowed with high-affinity toward A20 lymphoma cells.
Particularly, the use of an Id-peptide as probe allowed to obtain a uniform sensor surface
coating, thus enhancing capture ability also at low cell concentrations. Moreover, the biosen‐
sor was biocompatible and showed high repeatability as well as selectivity in label-free cell
detection.
The improved device opens the way to the development of unique diagnostic tools in point-
of-care testing for recognition and isolation of patient-specific neoplastic B cells during the
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minimal residual disease. Any idiotype peptide is ideally endowed with a unique, clone-
specific antigenic reactivity. Of course, this approach requires the selection of Id-peptides for
each patient through laborious and costly procedures. This might be overcome focusing on a
specific B-cell tumors, where a consistent number of patients share the same antigenic
reactivity against a restrict pool of Id-peptides. Nevertheless, this strategy can be utilized for
the characterization of other specific peptide–receptor interactions through the screening of a
recombinant phage library.
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